- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02895178
Lifestyles Of Health And Sustainability for Breast Cancer Survivors
Lifestyle Intervention for Breast Cancer Survivors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients and survivors of breast cancer present impaired physical fitness and various complications including acute and chronic pain, severe fatigue, limited range of motion, and bone loss attributable to anticancer treatments. Therefore, regular exercise during and following cancer treatments has been recommended to enhance physical capabilities and relieve side-effect severities, leading to an improved quality of life. Despite the known general benefits to patients with cancer, the effects of exercise on cancer-related biomarkers and their modulators remain unclear.
PRIMARY OBJECTIVES:
I. To determine whether a 12-week exercise intervention will improve components of health-related physical fitness by measuring cardiorespiratory fitness, muscular exercise capacity and flexibility in breast cancer survivors.
II. To determine whether a 12-week exercise intervention will improve risk parameters of metabolic disease by measuring changes in body composition, waist circumference, blood pressure, and circulating levels of glucose, insulin, lipids components and C-reactive protein in breast cancer survivors.
III. To determine whether a 12-week exercise intervention will conduce to changes of cancer-related biomarker by measuring in serum levels of dickkopf-related protein 1 (DKK1), secreted frizzled-related protein 1 (SFRP1), sclerostin, osteoprotegerin, osteopontin, growth differentiation factor 15 (GDF-15), insulin like growth factor 1 (IGF-1), and IGFBP-3 in breast cancer survivors.
IV. To determine whether a 12-week exercise intervention will result in a improvement in inflammatory cytokines and adipokines by measuring in serum levels of interleukin 1 beta (IL-1β), IL-10, IL-11, tumor necrosis factor alpha (TNFα), leptin and adiponectin in breast cancer survivors.
V. To determine whether a 12-week exercise intervention will conduce to changes of myokines by measuring in serum levels of brain-derived neurotrophic factor (BDNF), IL-8, IL-15, fatty acid-binding protein 3 (FABP3), leukemia inhibitory factor (LIF), follistatin, fractalkine, fibroblast growth factor 21 (FGF-21), osteonectin and irisin in breast cancer survivors.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jae Seung Chang, Ph.D
- Phone Number: +82-33-741-0296
- Email: godbless@yonsei.ac.kr
Study Locations
-
-
Gangwon-do
-
Wonju, Gangwon-do, Korea, Republic of
- Recruiting
- Center for Exercise medicine; Yonsei University
-
Contact:
- Jae Seung Chang, Ph.D
- Phone Number: +82-70-8826-0292
- Email: godbless@yonsei.ac.kr
-
Principal Investigator:
- Jae Seung Chang, Ph.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have diagnosed as a stage of I-III breast cancer
- Have undergone a lumpectomy or mastectomy
- Have completed neoadjuvant/adjuvant chemotherapy and able to initiate Exercise program
- Nonsmokers (i.e., not smoking during previous 12 months)
- Able to provide physician clearance to participate in exercise program for 12 weeks
Exclusion Criteria:
- History of chronic disease including diabetes, uncontrolled hypertension or thyroid disease
- Weight reduction >= 10% within past 6 months
- Metastatic disease
- Participate in more than 60 minutes of exercise per week in the past 6 months
- Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exercise in breast cancer survivors
Combined aerobic and strength exercise training for 12 weeks under supervision
|
Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
|
No Intervention: No exercise in breast cancer survivors
Lifestyle counseling and standard of care follow up for 12 weeks
|
|
Sham Comparator: Exercise in healthy subjects
Age-matched healthy subjects.
Combined aerobic and strength exercise training for 12 weeks under supervision
|
Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of health-related physical fitness components (1).
Time Frame: Changes from baseline aerobic capacity at 12 weeks
|
Aerobic capacity is assessed using multi-stage 20 meters shuttle run test (the maximum number of repetitions).
|
Changes from baseline aerobic capacity at 12 weeks
|
Changes of health-related physical fitness components (2).
Time Frame: Changes from baseline muscular endurance at 12 weeks
|
Muscular endurance is assessed using sit-up test for 30 seconds (the maximum number of repetitions).
|
Changes from baseline muscular endurance at 12 weeks
|
Changes of health-related physical fitness components (3).
Time Frame: Changes from baseline muscular strength at 12 weeks
|
Muscular strength is assessed by the maximum voluntary strength of handgrip (kg).
|
Changes from baseline muscular strength at 12 weeks
|
Changes of health-related physical fitness components (4).
Time Frame: Changes from baseline muscular power at 12 weeks
|
Muscular power is assessed using standing long jump test (the maximum horizontal distance of two trials, cm).
|
Changes from baseline muscular power at 12 weeks
|
Changes of health-related physical fitness components (5).
Time Frame: Changes from baseline agility at 12 weeks
|
Agility is assessed using 10 meters agility shuttle run test (the time taken to complete a 10 meters course is recorded, seconds).
|
Changes from baseline agility at 12 weeks
|
Changes of health-related physical fitness components (6).
Time Frame: Changes from baseline flexibility at 12 weeks
|
Flexibility is assessed using sit and reach test (the greater distance of two trials, cm)
|
Changes from baseline flexibility at 12 weeks
|
Changes of anthropometric parameters (1).
Time Frame: Changes from baseline waist circumference at 12 weeks
|
Waist circumference is measured at the midpoint between the lower rib margin and the iliac crest (expressed in cm).
|
Changes from baseline waist circumference at 12 weeks
|
Changes of anthropometric parameters (2).
Time Frame: Changes from baseline BMI at 12 weeks
|
BMI calculated as body weight / height (kg per square meters).
|
Changes from baseline BMI at 12 weeks
|
Changes of body composition parameters (1).
Time Frame: Changes from baseline body fat mass at 12 weeks
|
Body fat mass is measured by a bio-impedance analyzer (expressed as kg).
|
Changes from baseline body fat mass at 12 weeks
|
Changes of body composition parameters (2).
Time Frame: Changes from baseline lean body mass at 12 weeks
|
Lean body mass is measured by a bio-impedance analyzer (expressed as kg).
|
Changes from baseline lean body mass at 12 weeks
|
Changes of body composition parameters (3).
Time Frame: Changes from baseline percentage body fat at 12 weeks
|
Percentage body fat is calculated as body fat mass (kg) divided by weight (kg).
|
Changes from baseline percentage body fat at 12 weeks
|
Changes of serum levels of Wnt signaling-related molecules (1).
Time Frame: Changes from baseline serum levels of DKK1 at 12 weeks
|
The serum concentration of DKK1 is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 15.6 pg/ml; Standard curve range, 31.2 - 2,000 pg/ml, R&D systems).
|
Changes from baseline serum levels of DKK1 at 12 weeks
|
Changes of serum levels of Wnt signaling-related molecules (2).
Time Frame: Changes from baseline serum levels of Sclerostin at 12 weeks
|
The serum concentration of sclerostin is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 6.96 pg/ml; Standard curve range, 7.49 - 1,820 pg/ml, R&D systems).
|
Changes from baseline serum levels of Sclerostin at 12 weeks
|
Changes of serum levels of Wnt signaling-related molecules (3).
Time Frame: Changes from baseline serum levels of SFRP1 at 12 weeks
|
The serum concentration of SFRP1 is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 53 pg/ml; Standard curve range, 156 - 10,000 pg/ml, USCN Life Science Inc.).
|
Changes from baseline serum levels of SFRP1 at 12 weeks
|
Changes of serum levels of Wnt signaling-related molecules (4).
Time Frame: Changes from baseline serum levels of β-catenin at 12 weeks
|
The serum concentration of β-catenin is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 3.9 pg/ml; Standard curve range, 15.6 - 1000 pg/ml, Cusabio Biotech).
|
Changes from baseline serum levels of β-catenin at 12 weeks
|
Changes of serum levels of Wnt signaling-related molecules (5).
Time Frame: Changes from baseline serum levels of WISP-1 at 12 weeks
|
The serum concentration of WISP-1 is measured by commercial chemiluminescent immunoassay kits (Minimal detectable density, 0.97 pg/ml; Standard curve range, 2.74 - 2,000 pg/ml, USCN Life Science Inc.).
|
Changes from baseline serum levels of WISP-1 at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes of serum levels of cancer-related molecules (1).
Time Frame: Changes from baseline serum levels of osteoprotegerin at 12 weeks
|
The serum concentration of osteoprotegerin is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 3.62 pg/ml; Standard curve range, 81.4 - 19,770 pg/ml, R&D systems).
|
Changes from baseline serum levels of osteoprotegerin at 12 weeks
|
Changes of serum levels of cancer-related molecules (2).
Time Frame: Changes from baseline serum levels of osteopontin at 12 weeks
|
The serum concentration of osteopontin is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 413 pg/ml; Standard curve range, 3.4 - 826.9 ng/ml, R&D systems).
|
Changes from baseline serum levels of osteopontin at 12 weeks
|
Changes of serum levels of cancer-related molecules (3).
Time Frame: Changes from baseline serum levels of GDF-15 at 12 weeks
|
The serum concentration of GDF-15 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 1.2 pg/ml; Standard curve range, 34 - 8,270 pg/ml, R&D systems).
|
Changes from baseline serum levels of GDF-15 at 12 weeks
|
Changes of serum levels of adipokines (1).
Time Frame: Changes from baseline serum levels of adiponectin at 12 weeks
|
The serum concentration of adiponectin is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 0.891 ng/ml; Standard curve range, 3.9 - 250 ng/ml, R&D systems).
|
Changes from baseline serum levels of adiponectin at 12 weeks
|
Changes of serum levels of adipokines (2).
Time Frame: Changes from baseline serum levels of leptin at 12 weeks
|
The serum concentration of leptin is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 7.8 pg/ml; Standard curve range, 15.6 - 1,000 ng/ml, R&D systems).
|
Changes from baseline serum levels of leptin at 12 weeks
|
Changes of serum levels of myokines (1).
Time Frame: Changes from baseline serum levels of BDNF at 12 weeks
|
The serum concentration of BDNF is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 0.32 pg/ml; Standard curve range, 10.9 - 2,650 pg/ml, R&D systems).
|
Changes from baseline serum levels of BDNF at 12 weeks
|
Changes of serum levels of myokines (2).
Time Frame: Changes from baseline serum levels of IL-8 at 12 weeks
|
The serum concentration of IL-8 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 1.8 pg/ml; Standard curve range, 8.19 - 1,990 pg/ml, R&D systems).
|
Changes from baseline serum levels of IL-8 at 12 weeks
|
Changes of serum levels of myokines (3).
Time Frame: Changes from baseline serum levels of IL-15 at 12 weeks
|
The serum concentration of IL-15 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 1.01 pg/ml; Standard curve range, 7.7 - 18,700 pg/ml, R&D systems).
|
Changes from baseline serum levels of IL-15 at 12 weeks
|
Changes of serum levels of myokines (4).
Time Frame: Changes from baseline serum levels of FABP3 at 12 weeks
|
The serum concentration of FABP3 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 472 pg/ml; Standard curve range, 1.3 - 312.2 ng/ml, R&D systems).
|
Changes from baseline serum levels of FABP3 at 12 weeks
|
Changes of serum levels of myokines (5).
Time Frame: Changes from baseline serum levels of LIF at 12 weeks
|
The serum concentration of LIF is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 9.31 pg/ml; Standard curve range, 68.1 - 16,550 pg/ml, R&D systems).
|
Changes from baseline serum levels of LIF at 12 weeks
|
Changes of serum levels of myokines (6).
Time Frame: Changes from baseline serum levels of follistatin at 12 weeks
|
The serum concentration of follistatin is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 133 pg/ml; Standard curve range, 2.6 - 650 ng/ml, R&D systems).
|
Changes from baseline serum levels of follistatin at 12 weeks
|
Changes of serum levels of myokines (7).
Time Frame: Changes from baseline serum levels of fractalkine at 12 weeks
|
The serum concentration of fractalkine is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 64.8 pg/ml; Standard curve range, 1.3 - 325.8 ng/ml, R&D systems).
|
Changes from baseline serum levels of fractalkine at 12 weeks
|
Changes of serum levels of myokines (8).
Time Frame: Changes from baseline serum levels of FGF-21 at 12 weeks
|
The serum concentration of FGF-21 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 27 pg/ml; Standard curve range, 623 - 151,330 pg/ml, R&D systems).
|
Changes from baseline serum levels of FGF-21 at 12 weeks
|
Changes of serum levels of myokines (9).
Time Frame: Changes from baseline serum levels of SPARC (osteonectin) at 12 weeks
|
The serum concentration of SPARC (osteonectin) is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 97.9 pg/ml; Standard curve range, 3.4 - 829.9 ng/ml, R&D systems).
|
Changes from baseline serum levels of SPARC (osteonectin) at 12 weeks
|
Changes of serum levels of myokines (10).
Time Frame: Changes from baseline serum levels of irisin at 12 weeks
|
The serum concentration of irisin is measured by commercial enzyme-linked immunosorbent assay kits (Minimal detectable density, 1.29 ng/ml; Standard curve range, 0.1 - 1,000 ng/ml, Phoenix Pharmaceuticals).
|
Changes from baseline serum levels of irisin at 12 weeks
|
Changes of serum levels of inflammatory-related cytokines (1)
Time Frame: Changes from baseline serum levels of IL-1 beta at 12 weeks
|
The serum concentration of IL-1 beta is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 0.8 pg/ml; Standard curve range, 17.8 - 4,320 pg/ml, R&D systems).
|
Changes from baseline serum levels of IL-1 beta at 12 weeks
|
Changes of serum levels of inflammatory-related cytokines (2)
Time Frame: Changes from baseline serum levels of IL-10 at 12 weeks
|
The serum concentration of IL-10 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 1.6 pg/ml; Standard curve range, 13.7 - 3,340 pg/ml, R&D systems).
|
Changes from baseline serum levels of IL-10 at 12 weeks
|
Changes of serum levels of inflammatory-related cytokines (3)
Time Frame: Changes from baseline serum levels of IL-11 at 12 weeks
|
The serum concentration of IL-11 is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 24.7 pg/ml; Standard curve range, 0.5 - 125.4 ng/ml, R&D systems).
|
Changes from baseline serum levels of IL-11 at 12 weeks
|
Changes of serum levels of inflammatory-related cytokines (4)
Time Frame: Changes from baseline serum levels of TNF-alpha at 12 weeks
|
The serum concentration of TNF-alpha is measured using commercial luminex multiplexed cytokine assay panels (Minimal detectable density, 1.2 pg/ml; Standard curve range, 14 - 3,410 pg/ml, R&D systems).
|
Changes from baseline serum levels of TNF-alpha at 12 weeks
|
Changes of bone mineral density
Time Frame: Changes from baseline bone mineral density at 12 weeks
|
Bone mineral density is expressed as T-score, which is measured by a compact ultrasonometer at calcaneus (Achilles Express, GE LUNAR Corp., Madison, WI)
|
Changes from baseline bone mineral density at 12 weeks
|
Collaborators and Investigators
Investigators
- Study Chair: In Deok Kong, Professor, Yonsei University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOHAS-BCS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
Clinical Trials on Combined aerobic and strength exercise training
-
VA Office of Research and DevelopmentCompletedHeart FailureUnited States
-
Hacettepe UniversityCompleted
-
University of LisbonCompletedChronic Heart Failure | FragilityPortugal
-
Amsterdam UMC, location VUmcAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)CompletedType 2 Diabetes Mellitus | Insulin Sensitivity/ResistanceNetherlands
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)CompletedDiabetic | CardiovascularCanada
-
General Hospital Murska SobotaUniversity of Primorska; University of LjubljanaUnknownCoronary Artery Disease | Heart Failure With Reduced Ejection FractionSlovenia
-
Norwegian University of Science and TechnologyCompleted
-
Ukbe SirayderCompleted
-
Baltimore VA Medical CenterUniversity of Maryland, BaltimoreActive, not recruiting